Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic
acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor …

In addition to the well-known palliative effects of cannabinoids on some cancer-associated
symptoms, a large body of evidence shows that these molecules can decrease tumour …

Various reports have shown that cannabinoids (the active components of marijuana and
their derivatives) can reduce tumour growth and progression in animal models of cancer, in …

Abstract mTORC1 is hyperactive in multiple cancer types,. Here, we performed integrative
analysis of single cell transcriptomic profiling, paired T cell receptor (TCR) sequencing, and …

It is well-established that cannabinoids exert palliative effects on some cancer-associated
symptoms. In addition evidences obtained during the last fifteen years support that these …

Midkine is a heparin-binding cytokine or a growth factor with a molecular weight of 13 kDa.
Midkine binds to oversulfated structures in heparan sulfate and chondroitin sulfate. The …

The incidence of pancreatic ductal adenocarcinoma (PDAC) nearly equals its mortality rate,
partly because most PDACs are intrinsically chemoresistant and thus largely untreatable. It …

The heparin-binding growth factor midkine (MK) comprises a family with
pleiotrophin/heparin-binding growth-associated molecule. The biological phenomena in …

Cell–cell interactions are critical for transmitting signals among cells and maintaining their
normal functions from the single-cell level to tissues. In cancer studies, interactions between …

Midkine (MK) is a heparin-binding growth factor that promotes carcinogenesis and
chemoresistance. The tumour microenvironment (TME) can affect chemotherapy sensitivity …